Results 141 to 150 of about 680,290 (258)
Objective To develop, externally validate, and simplify a machine learning model to predict remission between 6 and 24 months in patients with rheumatoid arthritis (RA) initiating tumor necrosis factor inhibitors, JAK inhibitors, interleukin‐6 inhibitors, abatacept, or rituximab using data from 11 international registries in the JAK‐pot collaboration ...
Zubeyir Salis +22 more
wiley +1 more source
High Adhesion Superoleophobic Oil Microdroplets to Create Ocular Hypertension In Vivo. [PDF]
Hong E +9 more
europepmc +1 more source
Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis
Systemic sclerosis–associated interstitial lung disease (SSc‐ILD) is one of the leading causes of morbidity and mortality in SSc, affecting up to three‐quarters of patients. The disease course is highly heterogeneous, ranging from indolent, nonprogressive forms to rapidly progressive pulmonary fibrosis (PPF).
Devis Benfaremo +7 more
wiley +1 more source
From Interferon Signature to the Clinical Landscape: Type I Interferonopathies
Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz +13 more
wiley +1 more source
Bilateral Diffuse Anterior Scleritis With Ocular Hypertension Revealing Rheumatoid Arthritis. [PDF]
Loubna M +4 more
europepmc +1 more source
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation
Philip J. Mease +20 more
wiley +1 more source
Correlation of Mitochondrial Flavoprotein Fluorescence and Sectoral OCT in Patients with Glaucoma, Suspects, and Ocular Hypertension. [PDF]
Heaster-Ford T +14 more
europepmc +1 more source
Objective We evaluated baseline characteristics, treatment patterns, and outcomes in patients with systemic autoimmune rheumatic disease–associated progressive pulmonary fibrosis (SARD‐PPF) and evaluated whether outcomes differed by SARD subtype. Methods The ILD‐PRO Registry is a prospective multicenter US registry of patients with PPF.
Sonali J. Bracken +7 more
wiley +1 more source
Risk of Ocular Hypertension With Intravitreal Triamcinolone Compared to the Dexamethasone Implant. [PDF]
Chebolu AP +3 more
europepmc +1 more source
Cancer in Systemic Sclerosis: Clinical Associations and Prognostic Impact From the EUSTAR Registry
Objective Cancer represents a major cause of death in systemic sclerosis (SSc). Established risk factors are limited to specific subsets, particularly early diffuse anti‐RNA polymerase III (POLR3)–positive disease, needing further exploration. Methods We performed a nested case‐control study within the European Scleroderma Trials and Research group ...
Antonio Tonutti +52 more
wiley +1 more source

